Shire’s multi­bil­lion-dol­lar gam­ble on lanadelum­ab pays off with stel­lar PhI­II da­ta, quick mar­ket­ing ap­pli­ca­tion

When Shire bought out Dyax for up to $6.5 bil­lion in 2015, the big prize was a new drug for hered­i­tary an­gioede­ma dubbed DX-2930 which posed a di­rect threat to Cin­ryze, a fran­chise drug for the rare dis­ease play­er.

Thurs­day morn­ing, Shire CEO Flem­ming Orn­skov says their mul­ti-bil­lion dol­lar bet paid off with stel­lar Phase III da­ta for the drug, now called lanadelum­ab (SHP643).

A 300 mg dose of the drug twice a month de­liv­ered an 87% re­duc­tion in mean HAE at­tack fre­quen­cy, com­pared to 0% in the place­bo group. It hit the pri­ma­ry end­point with “high­ly” sta­tis­ti­cal­ly sig­nif­i­cant re­sults as well as all the sec­on­daries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER